WHO Declares Bundibugyo Virus Outbreak A Public Health Emergency Of International Concern (PHEIC) – 2026 Response Guidelines

The World Health Organization declared the Bundibugyo virus (BDBV) outbreak in the Democratic Republic of the Congo (DRC) and Uganda a Public Health Emergency of International Concern (PHEIC) on May 17, 2026, after consulting affected countries and assessing the risk. The IHR Emergency Committee, convened by WHO Director-General Tedros Adhanom Ghebreyesus on May 19, confirmed the classification but ruled out a pandemic emergency, citing the virus’s limited spread beyond the two nations. With no approved vaccines or therapeutics for BDBV—a rare Ebola relative—WHO issued tiered temporary recommendations** for 116 countries, prioritizing containment in high-risk zones while urging global vigilance.

---

Why the WHO declared a PHEIC—and why it’s not a pandemic

The Bundibugyo virus, which causes a severe hemorrhagic fever, has infected two confirmed cases in Uganda—both linked to transmission from the DRC, where the risk remains "very high", according to WHO’s May 22 risk assessment. Uganda’s risk is classified as "high" due to its cross-border exposure, but no secondary transmission has been documented there. The outbreak’s containment hinges on public health interventions—no vaccines or drugs exist, and experimental treatments are still in development.

"This is one of the most challenging operational environments we’ve faced," said a WHO spokesperson, citing armed conflict, displaced populations, and weak healthcare infrastructure in eastern DRC. The committee emphasized that contextual factors—such as community distrust and logistical hurdles—must shape the response.

Unlike the 2014–2016 West Africa Ebola outbreak (which killed over 11,000 and triggered a PHEIC), BDBV has not spread beyond DRC and Uganda, and its case-fatality rate is lower (historically ~40%, vs. ~50% for Ebola virus). However, WHO’s PHEIC designation reflects three key concerns:

1. Cross-border risk: Uganda’s cases confirm transmission across porous borders, a pattern seen in past Ebola outbreaks (e.g., Sudan in 2022).
2. Diagnostic gaps: Unlike Ebola virus, BDBV cannot be detected by the GeneXpert platform, forcing reliance on slower RT-PCR tests.
3. Operational fragility: DRC’s eastern provinces—where the outbreak is concentrated—are among the most insecure in the world, with active conflict involving armed groups disrupting response efforts.

---

WHO’s tiered response: What each country must do

WHO’s recommendations vary by risk level, targeting three groups: countries with active cases (DRC, Uganda), neighboring nations, and the rest of the world.

1. For DRC and Uganda (risk: "Very high" and "High")

Immediate actions include:

• Declaring a national health emergency and activating emergency operation centers to coordinate surveillance, contact tracing, and safe burials.
• Scaling up surveillance with dedicated teams in high-risk zones, including active case-finding for unexplained illnesses and 24-hour investigation of "alerts" (suspicious fever/death clusters).
• Enhancing lab capacity: Decentralizing RT-PCR testing (not GeneXpert) to reduce delays, with field labs meeting biosafety standards. Uganda’s two confirmed cases were identified via this method.
• Border security: Establishing cross-border "security corridors" for responders and exit screening at airports/ports, though no travel bans are recommended yet.
• Community engagement: Training traditional healers and religious leaders to promote hand hygiene, isolation, and dignified burials—critical in reducing stigma and improving compliance.

"The difference between success and failure here will be trust," said a WHO epidemiologist, noting that past Ebola responses in DRC collapsed when communities rejected interventions.

Challenges:

• No therapeutics: Experimental drugs (e.g., remdesivir, monoclonal antibodies) are in trials but not yet approved for BDBV.
• Laboratory shortages: Only two WHO-accredited labs in DRC can test for BDBV, creating backlogs.
• Conflict zones: Armed groups have attacked health workers in the past (e.g., 2018–2020 Ebola outbreak), complicating deployments.

2. For neighboring countries (risk: "High")

Nations sharing borders with DRC/Uganda (e.g., South Sudan, Rwanda, Burundi) must:

• Boost surveillance at ground crossings, airports, and ports, screening for fever + travel history to affected areas.
• Pre-position supplies: Stockpile PPE, safe-burial kits, and diagnostic tools near borders.
• Simulate outbreaks: Conduct drills for case detection, contact tracing, and evacuation of exposed travelers.
• Monitor contacts: Use airline passenger lists to track travelers from high-risk zones and share data with destination countries.

Example: Rwanda has already activated its Ebola rapid-response team and banned mass gatherings near the DRC border.

3. For all other countries (risk: "Low")

Low-risk nations (e.g., Europe, North America, Australia) face minimal direct threat but must:

• Prepare for repatriation: Plan to evacuate exposed nationals (e.g., healthcare workers) and provide post-exposure monitoring.
• Screen travelers: Disseminate BDBV case definitions to doctors and advise against travel to outbreak zones.
• Monitor imports: Test samples from travelers with fever arriving from DRC/Uganda, though no cases outside Africa have been reported.

---

What’s next: Research, vaccines, and the road ahead

With no approved treatments or vaccines, WHO is prioritizing:

1. Diagnostic validation: Comparing PCR platforms (e.g., Radione) to WHO’s gold standard to speed up testing.
2. Clinical trials: Accelerating therapeutics (e.g., Ebola drug mAb114, repurposed for BDBV) and vaccines (e.g., Ervebo, the only licensed Ebola vaccine, is being tested for cross-protection).
3. Surveillance expansion: Deploying rapid-response teams to high-risk border areas in DRC and Uganda.

"We’re in a race against time," said a WHO scientist, noting that BDBV’s incubation period (2–21 days) and asymptomatic spread complicate containment.

---

How this compares to past Ebola outbreaks

Outbreak	Virus	Cases (Confirmed)	PHEIC Declared?	Vaccine/Therapeutics	Key Challenge
2014–2016 West Africa	Ebola virus	28,652	Yes (2014)	Ervebo (2019)	Urban spread, weak healthcare
2018–2020 DRC	Ebola virus	3,481	Yes (2019)	mAb114 (2020)	Armed conflict, distrust
2022 Sudan	Sudan ebolavirus	142	Yes (2022)	None	Cross-border transmission
2026 DRC/Uganda	Bundibugyo	2 (Uganda)	Yes (2026)	None	No diagnostics, conflict zones

Key difference: BDBV’s lower fatality rate and limited spread reduce global alarm—but its diagnostic gaps and operational hurdles make containment harder than past outbreaks.

---

What readers should know

• Travel risk: WHO advises avoiding non-essential travel to eastern DRC and high-risk areas in Uganda. No travel bans are in place, but exit screening is being implemented.
• Symptoms: BDBV causes fever, fatigue, muscle pain, vomiting, and bleeding—similar to Ebola. Seek medical help immediately if exposed.
• Prevention: Hand hygiene, avoiding bushmeat, and safe burials are critical. No vaccine exists for BDBV.
• Global watch: Countries with weak healthcare systems (e.g., Central African Republic, South Sudan) are most vulnerable to importation.

---

Sources

• World Health Organization. Temporary recommendations on the Bundibugyo virus disease epidemic (2026).
• WHO Emergency Committee statement. May 19, 2026.
• CDC. Bundibugyo virus disease fact sheet.
• The Lancet. Ebola therapeutics pipeline update (2023).